The direct effect of dopamine on tumour cells is supported by studies in which dopaminergic drugs targeting DRD1 and DRD2 exert therapeutic effects in preclinical cancer models by inhibiting tumour proliferation and inducing death of tumour cells [45,46]. The gene discussed is DRD1; the disease is cancer.